Hyperion Therapeutics: Hyperion Therapeutics Receives Consensus Recommendation of "Hold" from Analysts (NASDAQ:HPTX)

Hyperion Therapeutics (NASDAQ:HPTX) has earned an average recommendation of "Hold" from the nine brokerages that are presently covering the company, AnalystRatings.Net reports. Five equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among brokers that have updated their [...]This article (Hyperion Therapeutics Receives Consensus Recommendation of "Hold" from Analysts (NASDAQ:HPTX)) was originally developed by and is property of American Banking News.Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.